Edition:
United Kingdom

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

53.97USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$53.97
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
590,862
52-wk High
$55.36
52-wk Low
$11.42

Select another date:

Fri, Nov 24 2017

BRIEF-Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program

* Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs

BRIEF-EMA recommends against approval after re-examination of Nektar's drug onzeald

* EU MEDICINES AGENCY RECOMMENDS AGAINST APPROVAL AFTER RE-EXAMINATION OF NEKTAR'S DRUG ONZEALD FOR TREATMENT OF BREAST CANCER WHICH HAS SPREAD TO BRAIN‍​ Source text (http://bit.ly/2zxBcXv) Further company coverage:

BRIEF-Nektar Therapeutics reports Q3 earnings per share $0.39

* Nektar Therapeutics reports financial results for the third quarter of 2017

BRIEF-Nektar Therapeutics presents preclinical data on NKTR-358

* Presents preclinical data on NKTR-358, a first-in-class regulatory T Cell stimulator, at 2017 American College of Rheumatology Annual Meeting Source text for Eikon: Further company coverage:

BRIEF-Nektar Therapeutics initiates propel clinical study

* Nektar Therapeutics initiates propel clinical study to evaluate combination of NKTR-214, a CD122-biased agonist, with tecentriq (atezolizumab) or keytruda (pembrolizumab) Source text for Eikon: Further company coverage:

BRIEF-Nektar Therapeutics and Eli Lilly got notice of early termination of waiting period related to license agreement

* Nektar Therapeutics - Co, Eli Lilly got notice of early termination of waiting period related to license agreement to co-develop NKTR-358 - SEC filing Source text:[http://bit.ly/2wFqKyD] Further company coverage:

BRIEF-Nektar Therapeutics Q2 loss per share $0.39

* Nektar therapeutics reports financial results for the second quarter of 2017

BRIEF-Eli Lilly and Nektar Therapeutics to develop, commercialize NKTR-358

* Lilly and Nektar Therapeutics announce alliance to develop and commercialize NKTR-358, an autoimmune therapy

EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug

European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit.

EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug

July 21 European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit.

Select another date: